Company registration number 04398605 (England and Wales)
UK HEALTHCARE CORPORATION LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
UK HEALTHCARE CORPORATION LIMITED
COMPANY INFORMATION
Director
S Ahmed
Company number
04398605
Registered office
Unit D Madison Place Central Park
Northampton Road
Manchester
M40 5AG
Auditor
Chadwick and Company (Manchester) Limited
Chartered Accountants
Statutory Auditors
Capital House
272 Manchester Road
Droylsden
Manchester
M43 6PW
Business address
Unit D Madison Place Central Park
Northampton Road
Manchester
M40 5AG
UK HEALTHCARE CORPORATION LIMITED
CONTENTS
Page
Strategic report
1 - 3
Director's report
4 - 5
Independent auditor's report
6 - 8
Group statement of comprehensive income
9
Group balance sheet
10
Company balance sheet
11 - 12
Group statement of changes in equity
13
Company statement of changes in equity
14
Group statement of cash flows
15
Notes to the financial statements
16 - 31
UK HEALTHCARE CORPORATION LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 1 -

The director presents the strategic report for the year ended 31 March 2025.

Review of the business

Whilst still challenging, the financial year 2024/2025 saw a slight reduction in operating profit to £2.69m, with turnover falling by 10.08% to £33.3m

During the period we had to adapt and change quickly to accommodate government and regulatory schemes such as Market-wide Half Hourly Settlement (MHHS), implementing this has resulted in increased operating, development and staffing costs.

Despite the challenges faced during the year, the overall gross profit figure slightly decreased from £5.32m in FY2023/​24 to £5.06m FY 2024/25. Gross profit margin has increased from 14.27% to 15.20%.

Administration expenses have increased by around 13% from the previous year, up to £2.5m from £2.2m; Driving factors of this increase include an increase in Bad debts, due to the end of the government relief schemes such as Energy Bill Discount Scheme (EBDS). We also had an increased development costs attributed to the MHHS implementation. This financial year also saw the development of the Customer Portal, ready for launch in the next financial year, this will enhance the customer’s experience.

Provisions for doubtful customer debts has marginally increased from the previous financial year, largely due to a small number of high value accounts defaulting on payments due to the withdrawal of EBDS. The group operates a robust credit control procedure which is constantly revised and stringently followed.

The group always seeks to employ people from the surrounding area where possible; during the previous 12 months staffing levels have remained consistent. With a focus on employing new sales staff to help achieve the planned growth of roughly 5% over the next FY. There are no current plans for any major expansion in administrative staffing, as we have developed our systems to handle company growth and the group regularly reviews workloads within each department to ensure there is sufficient depth of cover for each role.

 

The directors are satisfied with the operating profit of £2.69m given the current economic climate.

 

Cash reserves have increased year on year, and equity has been increasing the directors feel the group is very well placed to cope with all short-term obligations and the long-term growth aspirations of the company without the need to seek outside financing

 

UK HEALTHCARE CORPORATION LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
Principal risks and uncertainties

The principal risks and uncertainties are:

Wholesale Energy Prices and Market Volatility

Wholesale pricing has largely remained stable over the past year, with a slight decrease in some segments. The current market conditions reflect more favourable rates, with older, higher-priced contracts expiring and being replaced by more competitively priced agreements.

Notably, the reduction in turnover can primarily be attributed to the transition of these older, higher-priced contracts coming to an end. However, turnover has only decreased by approximately 10%, despite certain contracts in the portfolio having been priced at rates more than double the current market levels. This is a clear indication that the company has performed well, managing to maintain strong revenue despite the market adjustments.


Inflation has increased to 2.6%, the UK economy is facing huge challenges, and many small businesses are finding it increasingly difficult to continue to operate when many of their major overhead costs increasing. It is not only the unprecedented increases in energy costs which have driven inflationary pressures with many businesses also seeing huge increases in raw material and staffing costs. The current economic outlook and the fear of impending recession pose a concern to the company. If a sizeable amount of businesses ceases trading, then this may lead to an increase in credit control queries and unobtainable commercial debts for existing customers. The company must therefore be more aware of risk and exposure when prospecting for new or renewing business.

Competition

Last year saw the closure and mergers of some energy suppliers for various reasons. Our strategy for slow and steady growth, protects us from the potential over extension with regards to capital requirements and need for outside investment or funding.

 

Legislative and regulatory changes

 

The group's operations are subject to regulatory requirements, particularly in relation to the way it serves customers, the products and services it sells, its advertising, marketing and sales practices, its employment and environmental issues. Changes in laws and regulations and their enforcement may impact on the group's business in terms of costs, changes to business practices and restrictions on activities. The regulatory framework within the group's market continues to be fast changing with major activity required to modify the CRM and billing systems, to enable all customers to benefit from the use of Smart meters by 2025, these requirements have been satisfied.

The group operates a compliance regime which monitors legal and regulatory developments to ensure the appropriate training is provided and the necessary modifications to trading practices and policies are made. Regular reviews are conducted to ensure compliance with the increasing number of legal and regulatory developments.

FINANCIAL INSTRUMENTS

The group has a normal level of exposure to price, credit, liquidity and cash flow risks arising from

trading activities which are only conducted in sterling.

EMPLOYEE INVOLVEMENT

Employees are kept well-informed about the progress and position of the group by means of regular

departmental meetings.

UK HEALTHCARE CORPORATION LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
Key performance indicators

The directors monitor progress of the business with reference to the following key performance indicators:

 

2025

2024

Definition & method of calculation

 

 

 

 

Gross profit as a % of turnover

15.20%

14.32%

Profit before administrative and exceptional costs

 

 

 

 

Sales per staff member

£0.9M

£1.06M

Turnover divided by number of staff

 

 

 

 

Liquidity Ratio

1.32

1.27

Current assets divided by current liabilities

 

 

 

 

Cash Balances

£9.9M

£8.6M

 

 

In general, the directors are satisfied with the KPI's which continue to indicate a strong improved position, year on year.

On behalf of the board

S Ahmed
Director
19 December 2025
UK HEALTHCARE CORPORATION LIMITED
DIRECTOR'S REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 4 -

The director presents his annual report and financial statements for the year ended 31 March 2025.

Principal activities

The principal activity of the company and group continued to be that of energy purchase and management to the business sector and trade of electricity.

 

Results and dividends

The results for the year are set out on page 9.

Ordinary dividends were paid amounting to £1,314,000. The director does not recommend payment of a further dividend.

Director

The director who held office during the year and up to the date of signature of the financial statements was as follows:

S Ahmed
Auditor

Chadwick and Company (Manchester) Limited were appointed as auditor to the group and in accordance with section 485 of the Companies Act 2006, a resolution proposing that they be re-appointed will be put at a General Meeting.

Statement of director's responsibilities

The director is responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the director is required to:

 

 

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

UK HEALTHCARE CORPORATION LIMITED
DIRECTOR'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the auditor of the company is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the auditor of the company is aware of that information.

Medium-sized companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.

On behalf of the board
S Ahmed
Director
19 December 2025
UK HEALTHCARE CORPORATION LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF UK HEALTHCARE CORPORATION LIMITED
- 6 -
Opinion

We have audited the financial statements of UK Healthcare Corporation Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The director is responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

UK HEALTHCARE CORPORATION LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF UK HEALTHCARE CORPORATION LIMITED
- 7 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the director's report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of director

As explained more fully in the director's responsibilities statement, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the director is responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the parent company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

 

Our objectives are also are to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the group financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We considered and updated our knowledge of the company's specific industry and its regulatory environment, and reviewed the company's documentation surrounding the policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities. Based on this understanding, we identified and assessed the risks of material misstatement in the financial statements and designed and performed audit procedures in response to those risks.

We identified the key laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements, including the Ofgem regulations, Employment Law, UK Companies Act 2006 and all other laws and regulations relating to the business. We also gained knowledge of the legal and regulatory frameworks which do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty.

UK HEALTHCARE CORPORATION LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF UK HEALTHCARE CORPORATION LIMITED
- 8 -
Audit response to risks identified

The audit engagement team were made aware of the potential opportunities and incentives that may exist within the company for fraudulent activity and how and where fraud might occur or be concealed within the financial statements.

In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override of controls. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other manual adjustments; assessed whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.

In addition to the above, we designed procedures which included:

 

 

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Michael Chadwick FCA, FCCA (Senior Statutory Auditor)
For and on behalf of Chadwick and Company (Manchester) Limited, Statutory Auditor
Chartered Accountants
Chartered Accountants
Statutory Auditors
Capital House
272 Manchester Road
Droylsden
M43 6PW
Manchester
22 December 2025
UK HEALTHCARE CORPORATION LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025
- 9 -
2025
2024
Notes
£
£
Turnover
2
33,284,231
37,353,718
Cost of sales
(28,222,779)
(32,023,774)
Gross profit
5,061,452
5,329,944
Administrative expenses
(2,508,712)
(2,224,530)
Other operating income
138,468
150,651
Operating profit
3
2,691,208
3,256,065
Interest receivable and similar income
6
205,767
50,097
Interest payable and similar expenses
7
(35,499)
-
0
Fair value gains and losses on investment properties
12
31,268
-
0
Profit before taxation
2,892,744
3,306,162
Tax on profit
8
(672,355)
(646,940)
Profit for the financial year
2,220,389
2,659,222
Other comprehensive income
Revaluation of tangible fixed assets
69,672
-
0
Total comprehensive income for the year
2,290,061
2,659,222
Profit for the financial year is all attributable to the owner of the parent company.
Total comprehensive income for the year is all attributable to the owner of the parent company.

The profit and loss account has been prepared on the basis that all operations are continuing operations.

UK HEALTHCARE CORPORATION LIMITED
GROUP BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 10 -
2025
2024
Notes
£
£
£
£
Fixed assets
Goodwill
10
27,499
32,999
Other intangible assets
10
27,460
32,759
Total intangible assets
54,959
65,758
Tangible assets
11
712,397
664,291
Investment property
12
1,082,750
1,051,482
1,850,106
1,781,531
Current assets
Debtors
15
10,051,856
11,963,762
Cash at bank and in hand
9,917,836
8,606,810
19,969,692
20,570,572
Creditors: amounts falling due within one year
16
(15,478,528)
(16,936,069)
Net current assets
4,491,164
3,634,503
Total assets less current liabilities
6,341,270
5,416,034
Provisions for liabilities
Deferred tax liability
17
225,257
276,082
(225,257)
(276,082)
Net assets
6,116,013
5,139,952
Capital and reserves
Called up share capital
19
3
3
Revaluation reserve
443,659
373,987
Capital redemption reserve
3
3
Other reserves
413,396
413,396
Profit and loss reserves
5,258,952
4,352,563
Total equity
6,116,013
5,139,952

These financial statements have been prepared in accordance with the provisions relating to medium-sized groups.

The financial statements were approved and signed by the director and authorised for issue on 19 December 2025
19 December 2025
S Ahmed
Director
Company registration number 04398605 (England and Wales)
UK HEALTHCARE CORPORATION LIMITED
COMPANY BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 11 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
24,460
29,259
Tangible assets
11
712,397
664,291
Investment property
12
1,082,750
1,051,482
Investments
13
55,000
55,000
1,874,607
1,800,032
Current assets
Debtors
15
9,125,039
9,356,064
Cash at bank and in hand
8,060,082
7,107,221
17,185,121
16,463,285
Creditors: amounts falling due within one year
16
(13,025,894)
(12,990,970)
Net current assets
4,159,227
3,472,315
Total assets less current liabilities
6,033,834
5,272,347
Provisions for liabilities
Deferred tax liability
17
225,257
276,082
(225,257)
(276,082)
Net assets
5,808,577
4,996,265
Capital and reserves
Called up share capital
19
3
3
Revaluation reserve
443,659
373,987
Capital redemption reserve
3
3
Other reserves
413,396
413,396
Profit and loss reserves
4,951,516
4,208,876
Total equity
5,808,577
4,996,265
UK HEALTHCARE CORPORATION LIMITED
COMPANY BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025
31 March 2025
- 12 -

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £2,056,641 (2024 - £2,562,918 profit).

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved and signed by the director and authorised for issue on 19 December 2025
19 December 2025
S Ahmed
Director
Company registration number 04398605 (England and Wales)
UK HEALTHCARE CORPORATION LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 13 -
Share capital
Revaluation reserve
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
£
Balance at 1 April 2023
6
373,987
-
0
413,396
5,307,341
6,094,730
Year ended 31 March 2024:
Profit and total comprehensive income
-
-
-
-
2,659,222
2,659,222
Dividends
9
-
-
-
-
(114,000)
(114,000)
Redemption of shares
19
-
-
3
-
-
3
Reduction of shares
19
(3)
-
-
-
(3,500,000)
(3,500,003)
Balance at 31 March 2024
3
373,987
3
413,396
4,352,563
5,139,952
Year ended 31 March 2025:
Profit for the year
-
-
-
-
2,220,389
2,220,389
Other comprehensive income:
Revaluation of tangible fixed assets
-
69,672
-
-
-
69,672
Total comprehensive income
-
69,672
-
-
2,220,389
2,290,061
Dividends
9
-
-
-
-
(1,314,000)
(1,314,000)
Balance at 31 March 2025
3
443,659
3
413,396
5,258,952
6,116,013
UK HEALTHCARE CORPORATION LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 14 -
Share capital
Revaluation reserve
Capital redemption reserve
Profit and loss reserves
Total
Notes
£
£
£
£
£
£
Balance at 1 April 2023
6
373,987
-
0
413,396
5,259,958
6,047,347
Year ended 31 March 2024:
Profit and total comprehensive income for the year
-
-
-
-
2,562,918
2,562,918
Dividends
9
-
-
-
-
(114,000)
(114,000)
Redemption of shares
19
-
-
3
-
-
3
Reduction of shares
19
(3)
-
-
-
(3,500,000)
(3,500,003)
Balance at 31 March 2024
3
373,987
3
413,396
4,208,876
4,996,265
Year ended 31 March 2025:
Profit for the year
-
-
-
-
2,056,640
2,056,640
Other comprehensive income:
Revaluation of tangible fixed assets
-
69,672
-
-
-
69,672
Total comprehensive income
-
69,672
-
-
2,056,640
2,126,312
Dividends
9
-
-
-
-
(1,314,000)
(1,314,000)
Balance at 31 March 2025
3
443,659
3
413,396
4,951,516
5,808,577
UK HEALTHCARE CORPORATION LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2025
- 15 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash generated from operations
23
3,612,146
6,472,858
Interest paid
(35,499)
-
0
Income taxes paid
(1,155,933)
(213,428)
Net cash inflow from operating activities
2,420,714
6,259,430
Investing activities
Purchase of intangible assets
(140)
(750)
Purchase of tangible fixed assets
(1,315)
-
Interest received
205,767
50,097
Net cash generated from investing activities
204,312
49,347
Financing activities
Redemption of shares
-
0
(3,500,000)
Dividends paid to equity shareholders
(1,314,000)
(114,000)
Net cash used in financing activities
(1,314,000)
(3,614,000)
Net increase in cash and cash equivalents
1,311,026
2,694,777
Cash and cash equivalents at beginning of year
8,606,810
5,912,033
Cash and cash equivalents at end of year
9,917,836
8,606,810
UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 16 -
1
Accounting policies
Company information

UK Healthcare Corporation Limited (“the company”) is a private limited company domiciled and incorporated in England and Wales. The registered office is .

 

The group consists of UK Healthcare Corporation Limited and all of its subsidiaries.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:

 

1.2
Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries, joint ventures and associates are accounted for at cost less impairment.

 

Deferred tax is recognised on differences between the value of assets (other than goodwill) and liabilities recognised in a business combination accounted for using the purchase method and the amounts that can be deducted or assessed for tax, considering the manner in which the carrying amount of the asset or liability is expected to be recovered or settled. The deferred tax recognised is adjusted against goodwill or negative goodwill.

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 17 -
1.3
Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company UK Healthcare Corporation Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.

 

All financial statements are made up to 31 March 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.

1.4
Going concern

At the time of approving the financial statements, the director has a reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.5
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

The nature of the energy industry in the UK, in which the company operates, is such that revenue recognition

is subject to a degree of estimation. Calculation of revenues from gas and electricity sales include an

estimate of the value of electricity and gas supplied to customers based on the latest data provided in the

industry at a certain point in time. The will incorporate current data available and will take into consideration

the industry reconciliation process.

Gas and electricity contracts are recognised on a straight line basis over the period of the agreement.

Rental income is recognised over the period of the lease.

1.6
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

 

 

1.7
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 18 -

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents & licences
10% on cost
1.8
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
2% on cost
Leasehold improvements
10% on cost
Fixtures and fittings
20% on cost
Computers
25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

1.9
Investment property

Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value at the reporting end date. Changes in fair value are recognised in profit or loss.

 

1.10
Fixed asset investments

Equity investments are measured at fair value through profit or loss, except for those equity investments that are not publicly traded and whose fair value cannot otherwise be measured reliably, which are recognised at cost less impairment until a reliable measure of fair value becomes available.

 

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.11
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 19 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.12
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.13
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 20 -
Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 21 -
Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.14
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.15
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.16
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.17
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.18
Leases

Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 22 -
2
Turnover and other revenue
2025
2024
£
£
Turnover analysed by class of business
Gas
8,112,544
10,101,879
Electricity
25,117,919
27,251,839
Other
53,768
-
33,284,231
37,353,718
2025
2024
£
£
Other revenue
Interest income
205,767
50,097
3
Operating profit
2025
2024
£
£
Operating profit for the year is stated after charging:
Fees payable to the group's auditor for the audit of the group's financial statements
15,500
15,200
Depreciation of owned tangible fixed assets
22,881
26,681
Amortisation of intangible assets
10,939
10,988
4
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2025
2024
2025
2024
Number
Number
Number
Number
Directors
1
1
1
1
Accounts
6
5
6
5
IT
1
1
1
1
Sales
13
14
13
14
Administration
13
14
13
14
Total
34
35
34
35
UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
4
Employees
(Continued)
- 23 -

Their aggregate remuneration comprised:

Group
Company
2025
2024
2025
2024
£
£
£
£
Wages and salaries
1,126,822
1,072,089
1,126,822
1,072,089
Social security costs
109,900
101,346
109,900
101,346
Pension costs
125,721
23,433
125,721
23,433
1,362,443
1,196,868
1,362,443
1,196,868
5
Director's remuneration
2025
2024
£
£
Remuneration for qualifying services
11,180
13,729
Company pension contributions to defined contribution schemes
103,043
859
114,223
14,588
6
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
205,628
50,044
Other interest income
139
53
Total income
205,767
50,097
7
Interest payable and similar expenses
2025
2024
£
£
Other interest
35,499
-
8
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
723,180
834,059
Adjustments in respect of prior periods
-
0
(189,625)
Total current tax
723,180
644,434
UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
8
Taxation
2025
2024
£
£
(Continued)
- 24 -
Deferred tax
Origination and reversal of timing differences
(50,825)
2,506
Total tax charge
672,355
646,940

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
2,892,744
3,306,162
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2024: 25.00%)
723,186
826,541
Tax effect of expenses that are not deductible in determining taxable profit
(5,002)
9,281
Adjustments in respect of prior years
-
0
(189,607)
Permanent capital allowances in excess of depreciation
5,358
(42)
Deferred tax adjustments in respect of prior years
(50,825)
2,506
Tax at marginal rate
(362)
(1,739)
Taxation charge
672,355
646,940
9
Dividends
2025
2024
Recognised as distributions to equity holders:
£
£
Interim paid
1,314,000
114,000
UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 25 -
10
Intangible fixed assets
Group
Goodwill
Patents & licences
Total
£
£
£
Cost
At 1 April 2024
54,999
55,596
110,595
Additions
-
0
140
140
At 31 March 2025
54,999
55,736
110,735
Amortisation and impairment
At 1 April 2024
22,000
22,837
44,837
Amortisation charged for the year
5,500
5,439
10,939
At 31 March 2025
27,500
28,276
55,776
Carrying amount
At 31 March 2025
27,499
27,460
54,959
At 31 March 2024
32,999
32,759
65,758
Company
Patents & licences
£
Cost
At 1 April 2024
50,596
Additions
140
At 31 March 2025
50,736
Amortisation and impairment
At 1 April 2024
21,337
Amortisation charged for the year
4,939
At 31 March 2025
26,276
Carrying amount
At 31 March 2025
24,460
At 31 March 2024
29,259

More information on impairment movements in the year is given in note .

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 26 -
11
Tangible fixed assets
Group
Leasehold land and buildings
Leasehold improvements
Fixtures and fittings
Computers
Total
£
£
£
£
£
Cost or valuation
At 1 April 2024
648,518
141,042
5,626
62,913
858,099
Additions
-
0
-
0
895
420
1,315
Revaluation
43,732
-
0
-
0
-
0
43,732
At 31 March 2025
692,250
141,042
6,521
63,333
903,146
Depreciation and impairment
At 1 April 2024
12,970
121,051
4,505
55,282
193,808
Depreciation charged in the year
12,970
2,790
876
6,245
22,881
Revaluation
(25,940)
-
0
-
0
-
0
(25,940)
At 31 March 2025
-
0
123,841
5,381
61,527
190,749
Carrying amount
At 31 March 2025
692,250
17,201
1,140
1,806
712,397
At 31 March 2024
635,548
19,991
1,121
7,631
664,291
Company
Leasehold land and buildings
Leasehold improvements
Fixtures and fittings
Computers
Total
£
£
£
£
£
Cost or valuation
At 1 April 2024
648,518
141,042
5,626
62,913
858,099
Additions
-
0
-
0
895
420
1,315
Revaluation
43,732
-
0
-
0
-
0
43,732
At 31 March 2025
692,250
141,042
6,521
63,333
903,146
Depreciation and impairment
At 1 April 2024
12,970
121,051
4,505
55,282
193,808
Depreciation charged in the year
12,970
2,790
876
6,245
22,881
Revaluation
(25,940)
-
0
-
0
-
0
(25,940)
At 31 March 2025
-
0
123,841
5,381
61,527
190,749
Carrying amount
At 31 March 2025
692,250
17,201
1,140
1,806
712,397
At 31 March 2024
635,548
19,991
1,121
7,631
664,291

The following assets are carried at valuation. If the assets were measured using the cost model, the carrying amounts would be as follows:

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
11
Tangible fixed assets
(Continued)
- 27 -
Leasehold land & buildings
2025
2024
£
£
Group
Cost
280,559
280,559
Accumulated depreciation
(67,334)
(61,723)
Carrying value
213,225
218,836
Company
Cost
280,559
280,559
Accumulated depreciation
(67,334)
(61,723)
Carrying value
213,225
218,836
12
Investment property
Group
Company
2025
2025
£
£
Fair value
At 1 April 2024
1,051,482
1,051,482
Net gains or losses through fair value adjustments
31,268
31,268
At 31 March 2025
1,082,750
1,082,750

The fair value of the investment property has been arrived at on the basis of a valuation carried out at 16 September 2025 by Eddisons Commercial Limited, who are not connected with the company. The valuation was made on an open market value basis by reference to market evidence of transaction prices for similar properties.

13
Fixed asset investments
Group
Company
2025
2024
2025
2024
Notes
£
£
£
£
Investments in subsidiaries
14
-
0
-
0
55,000
55,000
UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
13
Fixed asset investments
(Continued)
- 28 -
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 April 2024 and 31 March 2025
55,000
Carrying amount
At 31 March 2025
55,000
At 31 March 2024
55,000
14
Subsidiaries

Details of the company's subsidiaries at 31 March 2025 are as follows:

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
D-Energi Trading Limited
Unit D, Madison Place, Central Park, Northampton Road, Manchester, M40 5AG
Trade of electricity
Ordianry
100.00
15
Debtors
Group
Company
2025
2024
2025
2024
Amounts falling due within one year:
£
£
£
£
Trade debtors
1,178,825
1,817,914
1,178,825
1,794,380
Amounts owed by group undertakings
-
-
2,067,681
1,662,248
Other debtors
33,386
1,940,331
33,410
941,331
Prepayments and accrued income
7,856,260
7,325,446
5,168,839
4,281,821
9,068,471
11,083,691
8,448,755
8,679,780
Amounts falling due after more than one year:
Other debtors
983,385
880,071
676,284
676,284
Total debtors
10,051,856
11,963,762
9,125,039
9,356,064
UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 29 -
16
Creditors: amounts falling due within one year
Group
Company
2025
2024
2025
2024
£
£
£
£
Trade creditors
2,755,848
2,793,076
2,645,403
2,625,575
Corporation tax payable
211,680
644,433
155,598
612,675
Other taxation and social security
504,370
566,850
29,978
23,721
Other creditors
210,963
165,058
114,201
82,080
Accruals and deferred income
11,795,667
12,766,652
10,080,714
9,646,919
15,478,528
16,936,069
13,025,894
12,990,970
17
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
2025
2024
Group
£
£
Accelerated capital allowances
100,408
219,261
Investment property
124,849
56,821
225,257
276,082
Liabilities
Liabilities
2025
2024
Company
£
£
Accelerated capital allowances
100,408
219,261
Investment property
124,849
56,821
225,257
276,082
Group
Company
2025
2025
Movements in the year:
£
£
Liability at 1 April 2024
276,082
276,082
Credit to profit or loss
(50,825)
(50,825)
Liability at 31 March 2025
225,257
225,257
UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 30 -
18
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
125,721
23,433

A defined contribution pension scheme is operated for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.

19
Share capital
Group and company
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
3
3
3
3
20
Operating lease commitments

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Group
Company
2025
2024
2025
2024
£
£
£
£
Within one year
9,659
-
4,292
-
Between two and five years
9,658
-
5,366
-
19,317
-
9,658
-
21
Related party transactions
Transactions with related parties

During the year the group entered into the following transactions with related parties:

Purchases
Purchases
2025
2024
£
£
Group
Other related parties
150,000
50,000
Other information

The group has taken advantage of the exemption provided in Financial Reporting Standard 102 Section 33 from disclosing related party transactions with wholly owned members of the group.

22
Controlling party

The director was the ultimate controlling party during the year under review and the preceding year.

UK HEALTHCARE CORPORATION LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 31 -
23
Cash generated from group operations
2025
2024
£
£
Profit after taxation
2,220,389
2,659,222
Adjustments for:
Taxation charged
672,355
646,940
Finance costs
35,499
-
0
Investment income
(205,767)
(50,097)
Fair value gain on investment properties
(31,268)
-
0
Amortisation and impairment of intangible assets
10,939
10,988
Depreciation and impairment of tangible fixed assets
22,881
26,681
Movements in working capital:
Decrease in debtors
1,911,906
180,395
(Decrease)/increase in creditors
(1,024,788)
2,998,729
Cash generated from operations
3,612,146
6,472,858
24
Analysis of changes in net funds - group
1 April 2024
Cash flows
31 March 2025
£
£
£
Cash at bank and in hand
8,606,810
1,311,026
9,917,836
2025-03-312024-04-01falsefalseCCH SoftwareCCH Accounts Production 2025.300S Ahmedfalse04398605bus:Consolidated2024-04-012025-03-31043986052024-04-012025-03-3104398605bus:Director12024-04-012025-03-3104398605bus:RegisteredOffice2024-04-012025-03-31043986052025-03-3104398605bus:Consolidated2025-03-3104398605bus:Consolidated2023-04-012024-03-31043986052023-04-012024-03-3104398605core:Goodwillbus:Consolidated2025-03-3104398605core:Goodwillbus:Consolidated2024-03-3104398605core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2025-03-3104398605core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2024-03-3104398605bus:Consolidated2024-03-31043986052024-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2025-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2024-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilar2025-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilar2024-03-3104398605core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2025-03-3104398605core:LeaseholdImprovementsbus:Consolidated2025-03-3104398605core:FurnitureFittingsbus:Consolidated2025-03-3104398605core:ComputerEquipmentbus:Consolidated2025-03-3104398605core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-03-3104398605core:LeaseholdImprovementsbus:Consolidated2024-03-3104398605core:FurnitureFittingsbus:Consolidated2024-03-3104398605core:ComputerEquipmentbus:Consolidated2024-03-3104398605core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-03-3104398605core:LeaseholdImprovements2025-03-3104398605core:FurnitureFittings2025-03-3104398605core:ComputerEquipment2025-03-3104398605core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-03-3104398605core:LeaseholdImprovements2024-03-3104398605core:FurnitureFittings2024-03-3104398605core:ComputerEquipment2024-03-3104398605core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2025-03-3104398605core:CurrentFinancialInstrumentsbus:Consolidated2024-03-3104398605core:ShareCapitalbus:Consolidated2025-03-3104398605core:ShareCapitalbus:Consolidated2024-03-3104398605core:RevaluationReservebus:Consolidated2025-03-3104398605core:RevaluationReservebus:Consolidated2024-03-3104398605core:CapitalRedemptionReservebus:Consolidated2025-03-3104398605core:CapitalRedemptionReservebus:Consolidated2024-03-3104398605core:OtherMiscellaneousReservebus:Consolidated2025-03-3104398605core:OtherMiscellaneousReservebus:Consolidated2024-03-3104398605core:RetainedEarningsAccumulatedLossesbus:Consolidated2025-03-3104398605core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-03-3104398605core:ShareCapital2025-03-3104398605core:ShareCapital2024-03-3104398605core:RevaluationReserve2025-03-3104398605core:RevaluationReserve2024-03-3104398605core:CapitalRedemptionReserve2025-03-3104398605core:CapitalRedemptionReserve2024-03-3104398605core:OtherMiscellaneousReserve2025-03-3104398605core:OtherMiscellaneousReserve2024-03-3104398605core:RetainedEarningsAccumulatedLosses2025-03-3104398605core:RetainedEarningsAccumulatedLosses2024-03-3104398605core:ShareCapitalbus:Consolidated2023-03-3104398605core:SharePremiumbus:Consolidated2023-03-3104398605core:CapitalRedemptionReservebus:Consolidated2023-03-31043986052023-03-3104398605core:ShareCapital2023-03-3104398605core:RevaluationReserve2023-03-3104398605core:CapitalRedemptionReserve2023-03-3104398605core:RetainedEarningsAccumulatedLosses2023-03-3104398605bus:Consolidated2023-03-3104398605core:Goodwill2024-04-012025-03-3104398605core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilar2024-04-012025-03-3104398605core:LandBuildingscore:LongLeaseholdAssets2024-04-012025-03-3104398605core:LeaseholdImprovements2024-04-012025-03-3104398605core:FurnitureFittings2024-04-012025-03-3104398605core:ComputerEquipment2024-04-012025-03-3104398605core:UKTaxbus:Consolidated2024-04-012025-03-3104398605core:UKTaxbus:Consolidated2023-04-012024-03-3104398605bus:Consolidated12024-04-012025-03-3104398605bus:Consolidated12023-04-012024-03-3104398605core:Goodwillbus:Consolidated2024-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2024-03-3104398605bus:Consolidated2024-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilar2024-03-3104398605core:Goodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-04-012025-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-04-012025-03-3104398605core:ExternallyAcquiredIntangibleAssetsbus:Consolidated2024-04-012025-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssets2024-04-012025-03-3104398605core:Goodwillbus:Consolidated2024-04-012025-03-3104398605core:PatentsTrademarksLicencesConcessionsSimilarbus:Consolidated2024-04-012025-03-3104398605core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-03-3104398605core:LeaseholdImprovementsbus:Consolidated2024-03-3104398605core:FurnitureFittingsbus:Consolidated2024-03-3104398605core:ComputerEquipmentbus:Consolidated2024-03-3104398605core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-03-3104398605core:LeaseholdImprovements2024-03-3104398605core:FurnitureFittings2024-03-3104398605core:ComputerEquipment2024-03-31043986052024-03-3104398605core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-04-012025-03-3104398605core:LeaseholdImprovementsbus:Consolidated2024-04-012025-03-3104398605core:FurnitureFittingsbus:Consolidated2024-04-012025-03-3104398605core:ComputerEquipmentbus:Consolidated2024-04-012025-03-3104398605core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-04-012025-03-3104398605core:Subsidiary12024-04-012025-03-3104398605core:Subsidiary112024-04-012025-03-3104398605core:CurrentFinancialInstrumentsbus:Consolidated2025-03-3104398605core:CurrentFinancialInstruments2025-03-3104398605core:CurrentFinancialInstruments2024-03-3104398605core:CurrentFinancialInstrumentsbus:Consolidated12025-03-3104398605core:CurrentFinancialInstrumentsbus:Consolidated12024-03-3104398605core:CurrentFinancialInstruments22025-03-3104398605core:CurrentFinancialInstruments32025-03-3104398605core:Non-currentFinancialInstrumentsbus:Consolidated42025-03-3104398605core:Non-currentFinancialInstrumentsbus:Consolidated52025-03-3104398605core:Non-currentFinancialInstruments62025-03-3104398605core:Non-currentFinancialInstruments72025-03-3104398605core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-03-3104398605core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3104398605core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3104398605bus:PrivateLimitedCompanyLtd2024-04-012025-03-3104398605bus:FRS1022024-04-012025-03-3104398605bus:Audited2024-04-012025-03-3104398605bus:ConsolidatedGroupCompanyAccounts2024-04-012025-03-3104398605bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP